---
title: "SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295668012.md"
description: "In Tel Aviv, Israel on August 12, 2026, SciSparc Ltd. (Nasdaq: SPRC) revealed that NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage pharmaceutical firm specializing in innovative therapies for central nervous system ailments, has obtained a patent from the Japanese Patent Office for their pharmacological blend titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.” This patent marks a significant milestone for NeuroThera, highlighting its commitment to advancing treatments in this field."
datetime: "2026-08-12T12:27:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295668012.md)
  - [en](https://longbridge.com/en/news/295668012.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295668012.md)
generator: "portal-rs"
---

# SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

In Tel Aviv, Israel on August 12, 2026, SciSparc Ltd. (Nasdaq: SPRC) revealed that NeuroThera Labs Inc. (TSXV: NTLX), a clinical-stage pharmaceutical firm specializing in innovative therapies for central nervous system ailments, has obtained a patent from the Japanese Patent Office for their pharmacological blend titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.” This patent marks a significant milestone for NeuroThera, highlighting its commitment to advancing treatments in this field.

### Related Stocks

- [SPRC.US](https://longbridge.com/en/quote/SPRC.US.md)

## Related News & Research

- [Scisparc posts audited 2025 net loss of USD 12.56 million](https://longbridge.com/en/news/296357022.md)
- [SciSparc subsidiary NeuroThera Labs raises C$5.4 million in private placements](https://longbridge.com/en/news/296225798.md)
- [Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement](https://longbridge.com/en/news/296161306.md)
- [Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2](https://longbridge.com/en/news/296129489.md)
- [NeuroThera Labs raises C$ 2.7 million in first tranche of non-brokered private placement at C$ 0.12 per unit](https://longbridge.com/en/news/295709422.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**